Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 12006314 Anti-cancer nuclear hormone receptor-targeting compounds

Patent 12006314 was granted and assigned to Nuvation Bio on June, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Son Minh Pham0

Jayakanth Kankanala0

Christopher Paul Miller0

Ihab S. Darwish0

Jeremy David Pettigrew0

David Hung0

Date of Patent

June 11, 2024

0

Patent Application Number

177350110

Date Filed

May 2, 2022

0

Patent Citations

US Patent 7449464 Phthalazinone derivatives

0

US Patent 7037919 Tetrahydroquinoline derivatives

0

US Patent 7038041 Selective nuclear receptor-targeted systems for delivery of cytotoxins to cancer cells for targeted photodynamic therapy

0

US Patent 7220730 Cancer specific radiolabeled conjugates regulated by the cell cycle for the treatment and diagnosis of cancer

0

US Patent 7981889 Phthalazinone derivatives

0

US Patent 8012976 Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)

0

US Patent 8129380 Phthalazinone derivatives

0

US Patent 8252802 Chemical compounds

0

...

Patent Primary Examiner

Matthew P Coughlin

0

CPC Code

0

0

0

0

0

0

0

0

...

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 12006314 Anti-cancer nuclear hormone receptor-targeting compounds

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.